IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

"ENHANCING PATIENT SAFETY THROUGH PHARMACOVIGILANCE: EFFECTIVE MONITORING AND REPORTING OF ADVERSE DRUG REACTIONS"

1Ms.Amruta Jadhav, 2Dr.Sachidanand S. Angadi, 3Mr.Raman Naiknaware, 4Dr.Rohit Chavhan, 5Dr

1B.Pharmacy Student, 2Principal, 3Assistant Professor, 4Assistant Professor

1Yash Institute of Pharmacy, Aurangabad,

2Yash Institute of Pharmacy, Aurangabad,

3Yash Institute of Pharmacy, Aurangabad,

4Yash Institute of Pharmacy, Aurangabad

ABSTRACT

Introduction: Adverse drug reactions (ADRs) represent a significant concern for patient safety and necessitate robust monitoring and reporting mechanisms. This systematic literature review delves into the landscape of ADR reporting, with a specific focus on leveraging the electronic health record (EHR) as a surveillance tool. Despite existing guidelines, variability in reporting standards persists among healthcare facilities worldwide.

Methods: A comprehensive search encompassing PubMed and the Cochrane Database of Systematic Reviews was conducted, targeting original articles and reports from reputable organizations. The review explores challenges encountered in ADR reporting, including under-reporting rates and interinstitutional variability. Potential strategies for improvement, such as direct reporting by consumers and enhanced healthcare provider education, are examined.

Results: Despite concerted efforts to promote ADR reporting, persistent barriers remain, including inadequate knowledge among healthcare professionals and logistical challenges in establishing robust reporting systems. Direct consumer reporting initiatives have shown promise in certain countries but warrant further investigation. Additionally, while the EHR presents promising opportunities for ADR monitoring, issues such as lack of standardization and alert fatigue hinder its effectiveness in practice.

Discussion: Addressing barriers to ADR reporting is imperative to strengthen pharmacovigilance systems and uphold patient safety standards. The review underscores the importance of standardized reporting practices,

technological advancements, and targeted educational interventions to optimize ADR monitoring and reporting efficacy.

Conclusion: By embracing targeted interventions and capitalizing on technological innovations, healthcare systems can bolster their capacity to detect, report, and mitigate ADRs effectively. This proactive approach not only enhances patient safety but also optimizes pharmacotherapy outcomes, ultimately advancing public health objectives.

Keywords: Adverse drug reactions (ADRs), Pharmacovigilance, Electronic health record (EHR), Under-reporting, Healthcare provider education, Patient safety

INTRODUCTION

To delve deeper into the importance of pharmacovigilance (PV) and the establishment of effective PV systems, it's crucial to understand the multifaceted nature of this discipline and its profound impact on public health. PV represents a systematic approach to monitoring the safety of medicinal products throughout their lifecycle, encompassing the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) and other drug-related problems. This comprehensive framework serves as a vital safeguard, protecting patients from potential harm while ensuring the optimal therapeutic benefit of medications.[1]

Detection lies at the forefront of PV activities, serving as the initial step in identifying and capturing information on adverse events associated with pharmaceutical products. Timely detection is paramount, as it enables healthcare professionals and regulatory authorities to intervene promptly, mitigating risks and preventing further harm to patients. Various mechanisms facilitate the detection of ADRs, including spontaneous reporting systems, electronic health records, and pharmacovigilance databases. These systems rely on healthcare professionals, patients, and other stakeholders to report adverse events, thereby contributing to the continuous surveillance of drug safety.[2,3]

Effective assessment of adverse events is essential for discerning causality, severity, and frequency, thereby informing risk management strategies and regulatory decisions. PV practitioners employ standardized methodologies, such as the WHO causality assessment criteria and the Naranjo algorithm, to systematically evaluate the likelihood of a drug's role in causing an adverse event. Additionally, signal detection algorithms and data mining techniques enable the identification of potential safety signals within large datasets, prompting further investigation and risk assessment. Through rigorous assessment, PV systems strive to distinguish genuine safety concerns from background noise, facilitating evidence-based decision-making.[4]

Understanding the underlying mechanisms of adverse reactions is crucial for elucidating the pharmacological, physiological, and genetic factors that contribute to individual susceptibility. Pharmacovigilance research encompasses pharmacokinetic and pharmacodynamic studies, pharmacogenomics, and post-marketing surveillance to unravel the complexities of drug safety. By elucidating the mechanisms through which drugs elicit adverse effects, researchers can identify biomarkers, genetic polymorphisms, and other risk factors that predispose certain individuals to adverse reactions. This deeper understanding informs personalized medicine approaches, wherein treatment regimens are tailored to individual patient characteristics, optimizing therapeutic outcomes while minimizing risks.[5]

Prevention represents the ultimate goal of pharmacovigilance efforts, embodying a proactive approach to mitigate risks and enhance patient safety. Through the identification of modifiable risk factors and the implementation of targeted interventions, PV systems aim to prevent adverse events before they occur, thereby averting potential harm and optimizing the therapeutic benefit of medications. Risk minimization strategies may include changes to product labeling, the implementation of risk management plans, and the dissemination of educational materials to healthcare professionals and patients. Furthermore, post-authorization safety studies and pharmacovigilance inspections contribute to ongoing risk mitigation efforts, ensuring the continued monitoring and improvement of drug safety profiles.[6]

In resource-limited settings, the establishment of effective PV systems presents unique challenges and opportunities. Limited financial resources, infrastructure, and trained personnel may impede the development and implementation of robust pharmacovigilance programs. However, strategic allocation of resources, capacity building initiatives, and collaboration among stakeholders can mitigate these challenges and accelerate progress in PV capacity building. The concept of reliance, wherein countries leverage the expertise and resources of peer regulators, non-governmental organizations, and international partners, serves as a cornerstone in overcoming barriers to implementation. By sharing best practices, harmonizing regulatory standards, and fostering knowledge exchange, nations can collectively strengthen their pharmacovigilance infrastructure, thereby enhancing patient safety and public health outcomes.[7,8]

In conclusion, pharmacovigilance is a critical component of public health, ensuring the safe and responsible use of medications through systematic monitoring, assessment, understanding, and prevention of adverse drug reactions. The establishment of effective PV systems requires a comprehensive approach, encompassing detection, assessment, understanding, and prevention of adverse events, as well as collaboration among stakeholders and capacity building initiatives. By prioritizing patient safety and leveraging available resources judiciously, countries can strengthen their pharmacovigilance infrastructure and enhance public health outcomes for all.

Historical overview over Pharmacovigilance

The origins of pharmacovigilance can be traced back over 170 years ago, although it wasn't formally recognized under this term at that time. Instead, it emerged as a structured activity within the professional health field, driven by the imperative to monitor the risk-benefit ratio of drugs and enhance patient safety and quality of life. The historical evolution of pharmacovigilance reflects a journey marked by significant milestones, ranging from early reports communicated through letters or warnings by clinicians to the emergence of modern, ultra-structured electronic registries. Understanding this trajectory is crucial for appreciating the profound impact pharmacovigilance has had on public health and pharmacology, as well as for identifying the challenges that lie ahead.

The historical timeline of pharmacovigilance illustrates the progression from rudimentary reporting mechanisms to sophisticated surveillance systems. Initially, adverse drug reactions were informally communicated through letters or warnings to publishers of prominent scientific journals, reflecting the anecdotal nature of early pharmacovigilance efforts. Over time, the recognition of the need for systematic monitoring led to the establishment of formal reporting systems and regulatory frameworks, laying the groundwork for modern pharmacovigilance practices.[9–11]

The evolution of pharmacovigilance can be characterized by the development of standardized methodologies and classification systems for adverse drug reactions. Spontaneous reporting, which forms the backbone of contemporary pharmacovigilance, emerged as the predominant method for detecting adverse events. This approach is particularly effective in identifying type B effects, which are often allergic or idiosyncratic reactions occurring in a minority of patients and are unrelated to dosage. Additionally, spontaneous reporting facilitates the detection of unusual type A effects, which are dosage-related and linked to the pharmacological effects of the drug. The etymology of the term "pharmacovigilance" sheds light on its core principles. Derived from the Greek "pharmakon," meaning medicinal substance, and the Latin "vigilia," meaning to keep watch, pharmacovigilance encapsulates the vigilant monitoring of drugs to ensure their safety and efficacy. This linguistic origin underscores the proactive nature of pharmacovigilance, emphasizing the importance of ongoing surveillance and vigilance in safeguarding public health.

The historical evolution of pharmacovigilance not only highlights past achievements but also underscores the challenges that lie ahead. As drug development continues to advance and new therapeutic modalities emerge, pharmacovigilance must adapt to address evolving risks and uncertainties. Emerging technologies, such as artificial intelligence and big data analytics, offer opportunities to enhance pharmacovigilance capabilities, but also pose challenges related to data privacy and interpretation.[12–14]

The historical overview of pharmacovigilance provides valuable insights into its evolution as a critical component of public health and pharmacology. From its humble beginnings to its current state of sophistication, pharmacovigilance has played a pivotal role in ensuring the safety and efficacy of medicinal products. By understanding the lessons of the past and embracing innovation, pharmacovigilance can continue to evolve and meet the challenges of the future, ultimately advancing the goal of improving patient outcomes and enhancing public health.



Timeline of the historical evolution

The review serves a vital purpose in the domain of pharmacovigilance by addressing the pervasive issue of under-reporting of adverse drug reactions (ADRs) within spontaneous reporting systems. Such systems rely on healthcare professionals and other stakeholders to voluntarily report ADRs, forming a crucial component of pharmacovigilance efforts. By estimating the extent of under-reporting and investigating potential variations

across different types of ADRs, the review aims to shed light on the gaps in ADR surveillance and reporting mechanisms.

Methodology of Literature Search:

The methodology employed in the review involved a systematic literature search to identify relevant studies providing numerical estimates of under-reporting. This approach ensures a comprehensive and rigorous selection process, minimizing bias and maximizing the inclusivity of studies across diverse methodologies and settings. By including studies regardless of their methodology or setting, such as hospital or general practice settings, the review captures a wide range of perspectives and experiences related to ADR reporting.

Data Extraction and Analysis:

Data extraction and analysis procedures were conducted meticulously to ensure the reliability and validity of the findings. Estimates of under-reporting were either directly extracted from published studies or calculated from the available data, following standardized protocols. By expressing these estimates as percentages of ADRs detected through intensive data collection but not reported to spontaneous reporting systems, the review provides a quantitative assessment of under-reporting rates, facilitating comparisons across studies and settings.

Study Characteristics:

The inclusion of thirty-seven studies from twelve countries reflects the global scope of the under-reporting issue and the diverse methodologies employed in ADR surveillance. These studies utilize a wide variety of surveillance methods, ranging from retrospective chart reviews to prospective cohort studies, underscoring the complexity of ADR reporting and detection. By encompassing studies from different countries and healthcare settings, the review captures the heterogeneity of ADR reporting practices and the need for tailored interventions.

Overall Under-Reporting Rates:

The calculated median under-reporting rate of 94% across all thirty-seven studies highlights the magnitude of the under-reporting problem within spontaneous reporting systems. This finding underscores the significant gaps in ADR surveillance and reporting, indicating that the majority of ADRs are not captured by existing reporting mechanisms. Such high under-reporting rates raise concerns about the reliability and completeness of pharmacovigilance data, potentially compromising patient safety and public health.

Comparison Across Settings:

The lack of significant differences in median under-reporting rates between general practice and hospital-based studies suggests that under-reporting is a systemic issue transcending different healthcare settings. This finding underscores the need for comprehensive strategies to address under-reporting across the entire healthcare continuum, rather than focusing solely on specific settings. By recognizing the systemic nature of the under-reporting problem, policymakers and healthcare stakeholders can implement targeted interventions to improve ADR surveillance and reporting practices.

Differences in ADR Severity:

The observed variations in under-reporting rates between general practice and hospital-based studies, particularly concerning the severity of ADRs, highlight the complexities inherent in ADR reporting. While some studies indicate higher under-reporting rates for all ADRs compared to more serious or severe ADRs in general practice settings, hospital-based studies still exhibit high under-reporting rates for serious or severe ADRs. These findings underscore the need for nuanced approaches to ADR reporting, considering factors such as severity, clinical context, and healthcare provider awareness and training.

Specific ADR-Drug Combinations:

The lower median under-reporting rates observed for studies investigating specific serious or severe ADR-drug combinations suggest that certain ADRs may receive greater attention or scrutiny within spontaneous reporting systems. However, the overall high under-reporting rate of 85% underscores the persistent challenges in ADR surveillance and reporting, even for specific ADR-drug combinations. This finding underscores the need for targeted interventions to improve reporting practices for high-risk ADRs, thereby enhancing patient safety and pharmacovigilance effectiveness.

Implications and Future Directions:

The implications of the review findings extend beyond the realm of pharmacovigilance, encompassing broader public health considerations and policy implications. The evidence of significant and widespread under-reporting of ADRs underscores the urgency of addressing gaps in ADR surveillance and reporting mechanisms. Future research should focus on assessing the impact of under-reporting on public health decisions and evaluating the effectiveness of initiatives aimed at improving reporting practices, such as internet reporting and direct patient reporting. Additionally, efforts to enhance education and training for healthcare professionals are essential to address the root causes of under-reporting and promote a culture of pharmacovigilance awareness and vigilance, particularly in resource-limited settings like rural areas of India. By addressing these challenges and embracing innovative solutions, stakeholders can enhance ADR monitoring and reporting mechanisms, ultimately advancing patient safety and improving public health outcomes.

Pharmacovigilance (PV) stands as a crucial discipline dedicated to the detection, collection, assessment, understanding, and prevention of adverse effects associated with pharmaceuticals. Its overarching objective is to ensure the safety of medicines and patients by meticulously monitoring and reporting all adverse drug reactions (ADRs) linked to prescribed medication usage. The significance of PV becomes evident when considering that a considerable proportion of hospitalization cases, ranging from 0.2% to 24%, are attributed to ADRs, with approximately 3.7% of these cases resulting in lethal outcomes. Several factors contribute to this phenomenon, including the proliferation of prescribed drugs, the influx of new medicines into the market, deficiencies in PV systems for ADR monitoring, and a lack of awareness and knowledge regarding ADR reporting among healthcare providers and patients.

The ramifications of severe ADRs are profound, extending beyond clinical implications to encompass substantial medical and economic consequences. Such adverse events often translate into prolonged hospital stays, heightened treatment costs, increased mortality risks, and a myriad of other complications. Therefore, prompt and comprehensive ADR reporting is paramount to mitigate further harm stemming from prescribed medications.

In India, the rate of ADR reporting stands at less than 1%, significantly lower than the global average of 5%. This discrepancy underscores the urgent need for heightened awareness and education regarding PV and ADR monitoring among healthcare professionals and patients alike. Bridging this gap is essential to enhance patient safety and optimize healthcare outcomes across the nation.[15–19]

The primary objective of this review is to elucidate the current landscape of ADR reporting methods in rural areas of India while exploring potential futuristic approaches to address existing challenges. To achieve this goal, a thorough literature search was conducted using various databases, including PubMed, Google Scholar, and the Indian Citation Index, to gather pertinent resources pertaining to ADR monitoring and reporting practices in both urban and rural settings.

Spontaneous reporting emerges as the predominant PV method utilized for ADR reporting in India, encompassing both urban and rural areas. However, evidence indicates a glaring lack of effective ADR reporting

mechanisms in rural regions, leading to significant underreporting and exacerbating the threat posed to the rural population.

To address these challenges, a multifaceted approach is warranted, incorporating innovative strategies and leveraging emerging technologies. Enhancing awareness and education regarding PV and ADR reporting among healthcare professionals and patients is imperative. Additionally, the integration of telecommunication, telemedicine, social media platforms, and electronic medical records can facilitate efficient ADR monitoring and reporting in remote rural areas. Furthermore, the application of artificial intelligence holds promise in streamlining ADR detection and assessment processes, thereby enhancing patient safety and optimizing healthcare delivery.

In conclusion, while the current scenario of ADR reporting in rural areas of India presents formidable challenges, there exists a myriad of futuristic approaches and technological innovations that hold the potential to revolutionize PV practices. By embracing these strategies and fostering collaboration among stakeholders, India can transcend existing barriers and establish a robust ADR monitoring and reporting infrastructure, ultimately safeguarding the health and well-being of its rural population.



Introduction to Literature Review:

A comprehensive systematic review of the literature was conducted using reputable databases such as PubMed and the Cochrane Database of Systematic Reviews. The search encompassed original articles, reports from reputable organizations such as the WHO and FDA, as well as reports from the Institute of Medicine. The focus of this review was to examine the landscape of adverse drug reaction (ADR) reporting, which is crucial for detecting uncommon ADRs once drugs are on the market. While many countries have regulatory bodies overseeing ADR reporting, there remains variability in reporting standards among healthcare facilities. Despite the existence of national and international guidelines, there is still room for improvement in ADR reporting rates among consumers and healthcare professionals.[20–24]

Purpose of the Review:

The primary objective of this review is to address the challenges and opportunities in adverse drug reaction (ADR) monitoring, particularly focusing on the utilization of the electronic health record (EHR) as a tool for ADR surveillance. ADRs pose significant risks to patient safety and can lead to morbidity and mortality. The

EHR presents a promising avenue for ADR monitoring, primarily through drug allergy data and pharmacogenomics. However, recent research has identified several limitations in using the EHR for ADR monitoring, including lack of standardization, incomplete documentation, and alert fatigue. Thus, this review aims to explore current practices, identify areas for improvement, and propose strategies to optimize ADR monitoring using the EHR.

Background and Challenges in ADR Reporting:

The review highlights the challenges associated with under-reporting of adverse drug reactions (ADRs) and its impact on pharmacovigilance systems worldwide. Despite efforts to promote ADR reporting, barriers such as inadequate knowledge among healthcare professionals, perceptions towards reporting, and challenges in establishing reporting systems in hospitals persist. Direct reporting by healthcare consumers has shown promise in improving ADR reporting rates in some countries, but limited research exists on its outcomes. To address these challenges, the review suggests measures such as greater involvement of nurses and pharmacists in reporting, simplifying reporting processes through electronic means, educational interventions for healthcare providers, and raising awareness among caregivers and recipients.

DISCUSSION

Enhancing Patient Safety through Pharmacovigilance

Pharmacovigilance stands as a cornerstone in the realm of healthcare, with its primary aim being the continual monitoring and reporting of adverse drug reactions (ADRs) to ensure patient safety. This discussion delves into the critical role of pharmacovigilance in identifying and mitigating ADRs, explores current challenges and opportunities in ADR monitoring and reporting, and underscores the imperative of advancing pharmacovigilance practices to enhance patient safety.

Importance of Pharmacovigilance:

Pharmacovigilance plays a pivotal role in safeguarding patient safety by systematically monitoring and analyzing the safety profile of medications post-market approval. The identification and reporting of ADRs are essential for early detection of potential risks associated with pharmaceuticals, facilitating timely intervention and risk mitigation strategies. By scrutinizing adverse events occurring in real-world clinical settings, pharmacovigilance contributes to the continuous evaluation of drug safety and informs regulatory decisions regarding medication use.

Current Challenges in ADR Monitoring and Reporting:

Despite the inherent importance of pharmacovigilance, several challenges hinder its effectiveness in ADR monitoring and reporting. One significant challenge is under-reporting, wherein healthcare professionals may fail to report ADRs due to factors such as lack of awareness, time constraints, or uncertainty about causality. Furthermore, interinstitutional variability in reporting standards and practices complicates the aggregation and analysis of ADR data, impeding efforts to identify emerging safety signals. Additionally, the lack of standardized terminology and classification systems for ADRs poses challenges in data interpretation and comparability across different healthcare settings.

Opportunities for Improvement:

Addressing the challenges in ADR monitoring and reporting necessitates a multifaceted approach involving various stakeholders, including healthcare professionals, regulatory agencies, pharmaceutical companies, and patients. Enhanced education and training programs for healthcare providers can raise awareness about the

importance of ADR reporting and equip them with the necessary knowledge and skills to recognize and report adverse events effectively. Standardization of reporting processes and terminology, along with the implementation of electronic reporting systems, can streamline ADR data collection and facilitate more efficient analysis and dissemination of safety information.

Utilizing Technology for ADR Surveillance:

The advent of technology, particularly electronic health records (EHRs), presents significant opportunities to enhance ADR surveillance and reporting. EHRs offer a comprehensive platform for capturing and documenting patient data, including medication histories, clinical notes, and laboratory results. By integrating decision support tools and alerts within EHR systems, healthcare providers can receive real-time notifications about potential ADRs, enabling timely intervention and proactive management of patient safety. Furthermore, data mining and artificial intelligence techniques can be leveraged to analyze large volumes of electronic health data and identify patterns indicative of ADRs, facilitating early detection and mitigation of risks.

Enhancing Patient Engagement:

In addition to healthcare professionals, patients play a crucial role in pharmacovigilance by reporting their experiences with medications and adverse events. Empowering patients to participate actively in ADR reporting through initiatives such as direct patient reporting programs and patient-centered communication channels can augment pharmacovigilance efforts. By soliciting patient feedback and insights, healthcare providers can gain valuable perspectives on medication safety and efficacy, contributing to a more comprehensive understanding of ADRs and patient outcomes.

CONCLUSION

In conclusion, pharmacovigilance serves as a vital mechanism for monitoring and reporting ADRs to ensure patient safety throughout the medication lifecycle. Despite existing challenges such as under-reporting and variability in reporting standards, opportunities abound for enhancing pharmacovigilance practices through education, standardization, and technological innovation. By fostering collaboration among stakeholders and embracing advancements in healthcare technology, healthcare systems can strengthen their pharmacovigilance infrastructure, ultimately advancing patient safety and optimizing healthcare outcomes. Continued efforts to improve ADR monitoring and reporting are essential to mitigate risks associated with medication use and promote the safe and effective use of pharmaceuticals in clinical practice.

REFERENCE

1. Fuzier R, Lapeyre-Mestre M, Samii K, Montastruc JL. Adverse drug reactions to local anaesthetics: a review of the French pharmacovigilance database. Drug Saf. 2009;32(4):345–56.

2. Taboada Muñiz M, Alvarez Escudero J, Carceller J, Rodríguez J, Rodríguez Forja MJ, Cortes J, et al. [Sciatic nerve block by the lateral route at the level of the popliteal fossa with 0.75% ropivacine: advantages of a more proximal approach]. Rev Esp Anestesiol Reanim. 2003;50(7):340–5.

3. Wijeysundera DN, Bender JS, Beattie WS. Alpha-2 adrenergic agonists for the prevention of cardiac complications among patients undergoing surgery. Cochrane database Syst Rev. 2009 Oct;(4):CD004126.

4. Mwakawanga DL, Kilonzi M, Philipo EG, Martine A, Mbilinyi T, Kileo NF, et al. Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Providers' Experiences from Southern Highland Tanzania. Adv Pharmacol Pharm Sci. 2023;2023:5537592.

5. Mwakawanga Manase; Philipo, Erick G; Martine, Aron; Mbilinyi, Tusaligwe; Kileo, Nancy F; Mkinga,

Bryceson; Shonyella, Cleopatra Justine; Mohamedi, Juma A; Clement, Aurelia; Mwasomola, Davance; Mushy, Stella E; Sirili, Nathanael DLK. Pharmacovigilance and Adverse Drug Reactions Reporting: Healthcare Providers' Experiences from Southern Highland Tanzania. Adv Pharmacol Pharm Sci. 2023;2023:5537510–92.

6. Haines Johanna C; Summers, R. S.; Godman, Brian HM. M. Knowledge, attitudes and practices of health care professionals towards adverse drug reaction reporting in public sector primary health care facilities in a South African district. Eur J Clin Pharmacol. 2020;76(7):991–1001.

7. Suyagh Doaa; Abu Farha, Rana MF. Pharmacist's knowledge, practice and attitudes toward pharmacovigilance and adverse drug reactions reporting process. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2014;23(2):147–53.

8. Gidey Mohammedamin; Hailu, Berhane Yohannes; Asgedom, Solomon Weldegebreal; Niriayo, Yirga Legesse KS. Healthcare professionals knowledge, attitude and practice of adverse drug reactions reporting in Ethiopia: a cross-sectional study. BMJ Open. 2020;10(2):e034553-NA.

9. Sultana Paola; Trifirò, Gianluca JC. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73-7.

10. Adisa Tomilayo I. RO. Awareness, knowledge, attitude and practice of adverse drug reaction reporting among health workers and patients in selected primary healthcare centres in Ibadan, southwestern Nigeria. BMC Health Serv Res. 2019;19(1):926.

11. Schroeder SA. How many hours is enough? An old profession meets a new generation. Ann Intern Med. 2004;140(10):838–9.

12. Yun Myung Jin; Park, Eun-Hye; Kim, Sung Eun; Lee, Jae Hyun; Park, Jung Won; Hong, Chein Soo ISK. A comparison of active surveillance programs including a spontaneous reporting model for phamacovigilance of adverse drug events in a hospital. Korean J Intern Med. 2012;27(4):443–50.

13. Shenton AK. Strategies for ensuring trustworthiness in qualitative research projects. Educ Inf. 2004;22(2):63–75.

14. Said Nadia ASA. H. Adverse Drug Reaction Reporting Practices Among United Arab Emirates Pharmacists and Prescribers. Hosp Pharm. 2017;52(5):361–6.

15. S N. Importance of Pharmacovigilance and the Role of Healthcare Professionals. J Pharmacovigil. 2018;6(1):1–2.

16. Dreischulte Faiza; Muth, Christiane; Schmiedl, Sven; Haefeli, Walter Emil TS. Prescribing Cascades: How to Detect Them, Prevent Them, and Use Them Appropriately. Dtsch Arztebl Int. 2022;119(44):745-NA.

17. Sahu Rajni; Prasad, Pushpa; Roy, Amit; Chandrakar, Shashikant RKY. Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus. 2014;3(1):695.

18. Al Dweik Dawn; Kohen, Dafna E.; Yaya, Sanni RS. Factors affecting patient reporting of adverse drug reactions: a systematic review. Br J Clin Pharmacol. 2016;83(4):875–83.

19. Gyllensten Katja M.; Hägg, Staffan; Carlsten, Anders; Petzold, Max; Rehnberg, Clas; Jönsson, Anna K. HH. Economic impact of adverse drug events--a retrospective population-based cohort study of 4970 adults. PLoS One. 2014;9(3):0092061-NA.

20. Srisuriyachanchai Anthony R; Jarernsiripornkul, Narumol WC. Exploring Healthcare Professionals' Practices and Attitudes towards Monitoring and Reporting of Severe Adverse Drug Reactions. Healthc (Basel, Switzerland). 2022;10(6):1077.

21. Braun Victoria VC. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.

22. Fukushima Noha; Balakrishnan, Madhava Ram; Pal, Shanthi Narayan AI. Smartphone-based mobile applications for adverse drug reactions reporting: global status and country experience. BMC Med Inform Decis Mak. 2022;22(1):118-NA.

23. Katusiime Daniel; Lubinga, Solomon J. BS. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda. Afr Health Sci. 2016;15(4):1308–17.

24. Hartman Linda; van Puijenbroek, Eugène JH. A global view of undergraduate education in pharmacovigilance. Eur J Clin Pharmacol. 2017;73(7):1–9.